All In Biotech

Drug Trial Radar · NCT07691762

A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma

A Phase III, Randomized, Double-blind, Multicenter Study of SHR-8068 and Adebrelimab Plus Bevacizumab in Combination With TACE in Participants With Incurable Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 690 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

690

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Sep 2031

Study completion Sep 2031

Sponsor

Sponsor type
Industry
First posted
Jul 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma. Participants will continue treatment until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • SHR-8068 + Adebrelimab + BevacizumabDrug

    SHR-8068 + Adebrelimab + Bevacizumab, intravenous infusion, Transarterial Chemoembolization (TACE)

  • SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab PlaceboDrug

    SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo, intravenous infusion, Transarterial Chemoembolization(TACE)

  • SHR-8068 Placebo + Adebrelimab + BevacizumabDrug

    SHR-8068 Placebo + Adebrelimab + Bevacizumab, intravenous infusion, Transarterial Chemoembolization (TACE)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) assessed by investigatorTime frame: Until progression, assessed up to approximately 2 years.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.